Accepted Manuscript

New Drugs

Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors

Nithya Krishnamurthy, Razelle Kurzrock

PII: S0305-7372(17)30187-1


DOI: https://doi.org/10.1016/j.ctrv.2017.11.002

Reference: YCTRV 1699

To appear in: Cancer Treatment Reviews Cancer Treatment Re-

views

Received Date: 28 July 2017
Revised Date: 1 November 2017
Accepted Date: 3 November 2017



Please cite this article as: Krishnamurthy, N., Kurzrock, R., Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors, *Cancer Treatment Reviews Cancer Treatment Reviews* (2017), doi: https://doi.org/10.1016/j.ctrv.2017.11.002

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

ACCEPTED MANUSCRIPT

Targeting the Wnt/beta-catenin Pathway in Cancer: Update on Effectors and Inhibitors

Nithya Krishnamurthy¹. Razelle Kurzrock MD^{1,2}

Affiliations: ¹ Center for Personalized Cancer Therapy, UCSD Moores Cancer Center, University of California San Diego, La Jolla, CA, USA.

²Division of Hematology-Oncology, University of California San Diego, La Jolla, CA, USA

*To whom correspondence should be addressed:

Ms. Nithya Krishnamurthy
Center for Personalized Cancer Therapy
UC San Diego - Moores Cancer Center 3855 Health Sciences Drive, MC #0658
La Jolla, California 92093-0658
(858) 657 6410 Direct
(858) 822 2300 Fax
nithyamurthy9@gmail.com

Disclosures: Dr. Kurzrock receives research funding from Genentech, Merck, Serono, Pfizer, Sequenom, Foundation Medicine, and Guardant, as well as consultant fees from X Biotech, and Actuate Therapeutics and has an ownership interest in Curematch Inc.

Funding: Funded in part by National Cancer Institute grant P30 CA016672 and the Joan and Irwin Jacobs Fund philanthropic fund.

Download English Version:

https://daneshyari.com/en/article/8785933

Download Persian Version:

https://daneshyari.com/article/8785933

<u>Daneshyari.com</u>